Vifor Pharma AG researches, develops, produces, and markets pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. More Details
No risks detected for VIFN from our risk checks.
Flawless balance sheet with proven track record and pays a dividend.
Share Price & News
How has Vifor Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VIFN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: VIFN's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: VIFN underperformed the Swiss Pharmaceuticals industry which returned -5.9% over the past year.
Return vs Market: VIFN underperformed the Swiss Market which returned -0.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Vifor Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StKey Things To Consider Before Buying Vifor Pharma AG (VTX:VIFN) For Its Dividend
3 weeks ago | Simply Wall StVifor Pharma AG's (VTX:VIFN) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
1 month ago | Simply Wall StIs Vifor Pharma (VTX:VIFN) Using Too Much Debt?
Is Vifor Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: VIFN (CHF136.9) is trading below our estimate of fair value (CHF610.33)
Significantly Below Fair Value: VIFN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: VIFN is poor value based on its PE Ratio (54.7x) compared to the XE Pharmaceuticals industry average (23x).
PE vs Market: VIFN is poor value based on its PE Ratio (54.7x) compared to the Swiss market (24.5x).
Price to Earnings Growth Ratio
PEG Ratio: VIFN is poor value based on its PEG Ratio (4.8x)
Price to Book Ratio
PB vs Industry: VIFN is good value based on its PB Ratio (2.7x) compared to the CH Pharmaceuticals industry average (3.4x).
How is Vifor Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VIFN's forecast earnings growth (11.5% per year) is above the savings rate (-0.3%).
Earnings vs Market: VIFN's earnings (11.5% per year) are forecast to grow slower than the Swiss market (13.1% per year).
High Growth Earnings: VIFN's earnings are forecast to grow, but not significantly.
Revenue vs Market: VIFN's revenue (6.8% per year) is forecast to grow faster than the Swiss market (4.6% per year).
High Growth Revenue: VIFN's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VIFN's Return on Equity is forecast to be low in 3 years time (9.5%).
How has Vifor Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VIFN has high quality earnings.
Growing Profit Margin: VIFN's current net profit margins (8.3%) are higher than last year (5.6%).
Past Earnings Growth Analysis
Earnings Trend: VIFN's earnings have declined by 18.2% per year over the past 5 years.
Accelerating Growth: VIFN's earnings growth over the past year (61.9%) exceeds its 5-year average (-18.2% per year).
Earnings vs Industry: VIFN earnings growth over the past year (61.9%) exceeded the Pharmaceuticals industry 13.8%.
Return on Equity
High ROE: VIFN's Return on Equity (6.9%) is considered low.
How is Vifor Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: VIFN's short term assets (CHF1.3B) exceed its short term liabilities (CHF548.6M).
Long Term Liabilities: VIFN's short term assets (CHF1.3B) exceed its long term liabilities (CHF678.2M).
Debt to Equity History and Analysis
Debt Level: VIFN's debt to equity ratio (15.4%) is considered satisfactory.
Reducing Debt: VIFN's debt to equity ratio has reduced from 42.7% to 15.4% over the past 5 years.
Debt Coverage: VIFN's debt is well covered by operating cash flow (88.3%).
Interest Coverage: VIFN's interest payments on its debt are well covered by EBIT (239.4x coverage).
What is Vifor Pharma current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: VIFN's dividend (1.46%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.62%).
High Dividend: VIFN's dividend (1.46%) is low compared to the top 25% of dividend payers in the Swiss market (3.79%).
Stability and Growth of Payments
Stable Dividend: VIFN's dividends per share have been stable in the past 10 years.
Growing Dividend: VIFN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (79.8%), VIFN's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: VIFN's dividends in 3 years are forecast to be well covered by earnings (36.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stefan Schulze (55 yo)
Mr. Stefan Schulze has been the Chief Executive Officer at Vifor Pharma AG since May 14, 2020 and had been its President of the Executive Committee and Chief Operating Officer at Vifor Pharma AG since May ...
CEO Compensation Analysis
Compensation vs Market: Stefan's total compensation ($USD2.64M) is below average for companies of similar size in the Swiss market ($USD5.93M).
Compensation vs Earnings: Stefan's compensation has been consistent with company performance over the past year.
|Chief Executive Officer||0.67yr||CHF2.35m||0.010% |
|Chief Financial Officer||3.67yrs||no data||0.0057% |
|Head of Finance||5yrs||no data||no data|
|Head of Investor Relations & Treasury||no data||no data||no data|
|Group General Counsel||7yrs||no data||no data|
|Global Head Corporate Communications||no data||no data||no data|
|Chief Human Resources Officer||5.67yrs||no data||0.0045% |
|Chief Strategy Officer||5yrs||no data||0.037% |
|Head of Global Quality Management||10yrs||no data||no data|
|Head of Global Medical Affairs||5yrs||no data||no data|
|Head of Executive Search & Employer Branding||3yrs||no data||no data|
|Chief Business Officer||2.17yrs||no data||0.00013% |
Experienced Management: VIFN's management team is seasoned and experienced (5 years average tenure).
|Independent Chairman of the Board||0.67yr||CHF195.00k||0.00086% |
|Director||0.67yr||no data||no data|
|Honorary Chairman||0.67yr||CHF4.50m||0.44% |
|Independent Director||3.67yrs||CHF173.00k||0.076% |
|Independent Director||11yrs||CHF192.00k||0.013% |
|Independent Deputy Chairman & Lead Independent Director||2yrs||CHF238.00k||0.0084% |
|Independent Director||1.67yrs||CHF123.00k||no data|
|Independent Director||1.67yrs||CHF145.00k||no data|
Experienced Board: VIFN's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Vifor Pharma AG's company bio, employee growth, exchange listings and data sources
- Name: Vifor Pharma AG
- Ticker: VIFN
- Exchange: SWX
- Founded: 1872
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF8.864b
- Shares outstanding: 64.89m
- Website: https://www.viforpharma.com
Number of Employees
- Vifor Pharma AG
- Rechenstrasse 37
- Sankt Gallen
- St. Gallen
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VIFN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Feb 2003|
|G2AA||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Feb 2003|
|GNHA.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Feb 2003|
|0RPD||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Feb 2003|
|GNHA.Y||OTCPK (Pink Sheets LLC)||UNSPONSERED ADR||US||USD||Apr 2012|
|G2AB||DB (Deutsche Boerse AG)||UNSPONSERED ADR||DE||EUR||Apr 2012|
Vifor Pharma AG researches, develops, produces, and markets pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a soluti...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/18 18:12|
|End of Day Share Price||2021/01/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.